Jupiter Topco LLC Purchases Shares of 1,251,616 Carlsmed, Inc. $CARL

Jupiter Topco LLC acquired a new position in shares of Carlsmed, Inc. (NASDAQ:CARL) in the 2nd quarter, Holdings Channel reports. The institutional investor acquired 1,251,616 shares of the company’s stock, valued at approximately $12,992,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CARL. BNP Paribas Financial Markets acquired a new stake in shares of Carlsmed in the 3rd quarter valued at $33,000. JPMorgan Chase & Co. acquired a new position in Carlsmed in the third quarter valued at about $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Carlsmed during the third quarter worth about $42,000. Rhumbline Advisers acquired a new stake in shares of Carlsmed during the third quarter worth approximately $79,000. Finally, Wells Fargo & Company MN raised its stake in shares of Carlsmed by 61.7% in the fourth quarter. Wells Fargo & Company MN now owns 7,834 shares of the company’s stock valued at $97,000 after acquiring an additional 2,989 shares during the last quarter.

Analysts Set New Price Targets

A number of equities research analysts recently commented on CARL shares. Weiss Ratings upgraded Carlsmed from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Truist Financial boosted their price objective on Carlsmed from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Needham & Company LLC started coverage on Carlsmed in a research note on Wednesday, July 1st. They issued a “buy” rating and a $17.00 target price for the company. BTIG Research reaffirmed a “buy” rating and issued a $23.00 price target on shares of Carlsmed in a report on Wednesday, May 6th. Finally, Wall Street Zen upgraded shares of Carlsmed from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Carlsmed currently has an average rating of “Moderate Buy” and an average price target of $19.25.

Carlsmed Stock Up 0.8%

Shares of NASDAQ:CARL opened at $16.88 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 8.84 and a quick ratio of 8.66. The stock has a market cap of $460.82 million and a price-to-earnings ratio of -11.80. The company has a 50 day moving average of $12.84 and a 200-day moving average of $11.61. Carlsmed, Inc. has a one year low of $8.50 and a one year high of $17.23.

Carlsmed (NASDAQ:CARL) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.01. Carlsmed had a negative net margin of 57.42% and a negative return on equity of 38.06%. The business had revenue of $18.94 million for the quarter. On average, sell-side analysts forecast that Carlsmed, Inc. will post -1.5 earnings per share for the current year.

About Carlsmed

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).